tradingkey.logo

Neuropace Inc

NPCE

8.930USD

-0.060-0.67%
Close 08/04, 16:00ETQuotes delayed by 15 min
292.47MMarket Cap
LossP/E TTM

Neuropace Inc

8.930

-0.060-0.67%
More Details of Neuropace Inc Company
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.
Company Info
Ticker SymbolNPCE
Company nameNeuropace Inc
IPO dateApr 22, 2021
CEOMr. Joel D. Becker
Number of employees184
Security typeOrdinary Share
Fiscal year-endApr 22
Address455 N. Bernardo Avenue
CityMOUNTAIN VIEW
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94043
Phone16502372700
Websitehttps://www.neuropace.com/
Ticker SymbolNPCE
IPO dateApr 22, 2021
CEOMr. Joel D. Becker
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Frank M. Fischer
Mr. Frank M. Fischer
Independent Chairman of the Board
Independent Chairman of the Board
589.53K
+0.39%
Dr. Martha J. Morrell, M.D.
Dr. Martha J. Morrell, M.D.
Chief Medical Officer
Chief Medical Officer
74.39K
-1.77%
Mr. Patrick F. Williams
Mr. Patrick F. Williams
Chief Financial Officer
Chief Financial Officer
51.85K
--
Mr. Joseph S. (Joe) Lacob
Mr. Joseph S. (Joe) Lacob
Independent Director
Independent Director
37.35K
+2.98%
Ms. Rakhi Kumar, CPA
Ms. Rakhi Kumar, CPA
Independent Director
Independent Director
15.59K
+10.17%
Dr. Uri Geiger
Dr. Uri Geiger
Independent Director
Independent Director
12.04K
+10.46%
Mr. R. Scott (Scott) Huennekens
Mr. R. Scott (Scott) Huennekens
Independent Director
Independent Director
--
--
Ms. Renee Ryan
Ms. Renee Ryan
Independent Director
Independent Director
--
--
Mr. Joel D. Becker
Mr. Joel D. Becker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Lisa Andrade
Ms. Lisa Andrade
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Frank M. Fischer
Mr. Frank M. Fischer
Independent Chairman of the Board
Independent Chairman of the Board
589.53K
+0.39%
Dr. Martha J. Morrell, M.D.
Dr. Martha J. Morrell, M.D.
Chief Medical Officer
Chief Medical Officer
74.39K
-1.77%
Mr. Patrick F. Williams
Mr. Patrick F. Williams
Chief Financial Officer
Chief Financial Officer
51.85K
--
Mr. Joseph S. (Joe) Lacob
Mr. Joseph S. (Joe) Lacob
Independent Director
Independent Director
37.35K
+2.98%
Ms. Rakhi Kumar, CPA
Ms. Rakhi Kumar, CPA
Independent Director
Independent Director
15.59K
+10.17%
Dr. Uri Geiger
Dr. Uri Geiger
Independent Director
Independent Director
12.04K
+10.46%
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q1
FY2023
FY2022
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
22.52M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jun 4
Updated: Wed, Jun 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Accelmed Growth Partners Management Ltd
13.52%
OrbiMed Advisors, LLC
10.39%
Soleus Capital Management, L.P.
7.95%
Morgan Stanley & Co. LLC
7.70%
Polar Capital LLP
7.62%
Other
52.83%
Shareholders
Shareholders
Proportion
Accelmed Growth Partners Management Ltd
13.52%
OrbiMed Advisors, LLC
10.39%
Soleus Capital Management, L.P.
7.95%
Morgan Stanley & Co. LLC
7.70%
Polar Capital LLP
7.62%
Other
52.83%
Shareholder Types
Shareholders
Proportion
Private Equity
23.90%
Hedge Fund
20.38%
Investment Advisor/Hedge Fund
19.42%
Investment Advisor
13.63%
Research Firm
8.48%
Individual Investor
2.75%
Pension Fund
0.40%
Bank and Trust
0.04%
Insurance Company
0.02%
Other
10.96%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
183
29.20M
89.03%
-971.50K
2025Q1
183
29.76M
92.98%
+2.27M
2024Q4
144
26.53M
86.07%
-49.99K
2024Q3
134
26.01M
86.62%
-1.02M
2024Q2
129
25.88M
90.53%
+502.69K
2024Q1
131
24.82M
87.55%
-513.24K
2023Q4
113
24.06M
92.70%
-1.70M
2023Q3
103
24.86M
97.20%
-1.10M
2023Q2
106
24.30M
96.22%
-2.15M
2023Q1
107
24.47M
97.75%
-1.64M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Accelmed Growth Partners Management Ltd
4.43M
13.52%
--
--
Apr 09, 2025
OrbiMed Advisors, LLC
3.41M
10.39%
--
--
Mar 31, 2025
Soleus Capital Management, L.P.
2.61M
7.95%
+175.00K
+7.19%
Mar 31, 2025
Morgan Stanley & Co. LLC
2.52M
7.7%
+38.83K
+1.56%
Mar 31, 2025
Polar Capital LLP
2.50M
7.62%
-472.00K
-15.88%
Apr 09, 2025
First Light Asset Management, LLC
1.58M
4.83%
+1.58M
--
Mar 31, 2025
The Vanguard Group, Inc.
1.20M
3.65%
+140.78K
+13.32%
Mar 31, 2025
Armistice Capital LLC
1.15M
3.52%
+561.00K
+94.67%
Mar 31, 2025
Kent Lake PR LLC
950.00K
2.9%
-532.55K
-35.92%
Mar 31, 2025
DWS Investments UK Limited
923.92K
2.82%
+511.66K
+124.11%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Neuroscience and Healthcare ETF
0.63%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
iShares Russell 2000 Growth ETF
0.02%
Principal U.S. Small-Cap ETF
0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
View more
iShares Neuroscience and Healthcare ETF
Proportion0.63%
iShares Micro-Cap ETF
Proportion0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.03%
iShares Russell 2000 Growth ETF
Proportion0.02%
Principal U.S. Small-Cap ETF
Proportion0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI